Durham, NC, October 23, 2023–(BUSINESS WIRE)–Precision BioSciences, Inc. (NASDAQ: DTIL) is an advanced gene editing company developing its novel proprietary ARCUS® platform in vivo Gene editing therapeutics for complex gene editing, including gene insertion, excision and elimination, announced today that the company will demonstrate at HC Wainwright 4th The annual Hepatitis B Virus (HBV) Virtual Conference will be held on October 25, 2023.
Details of the virtual fireside chat are as follows:
Date: Wednesday, October 25, 2023
Time: 9:30 AM Eastern Time
The fireside chat will be held via webcast on October 25, 2023, under the Investors section of the Precision website: https://investor.precisionbiosciences.com/events-and-presentations. Archived replays will be available approximately 30 days after the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., an advanced gene editing company dedicated to improving lives (DTIL), differentiates its novel and proprietary ARCUS® genome editing platform from other technologies by its cutting pattern, smaller size and Simple structure. ARCUS is a highly precise and versatile genome editing platform designed with therapeutic safety, delivery and control in mind.Using ARCUS, the company’s pipeline includes in vivo Gene-editing drug candidates aim to provide durable treatments for the widest range of genetic diseases and infectious diseases for which there are currently no adequate treatments. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231023532015/en/
Contact information
Investor and media contact information:
Mae Burris
Senior Financial Director and Corporate Controller
Mei.Burris@precisionbiosciences.com